Abstract :
The Strategic Plan for Biodefense Research of the U.S. Department of Health and Human Services emphasizes the urgent need for medications that can efficiently target many pathogens as part of our readiness for infectious disease threats. Azithromycin is a notable broad-spectrum therapeutic highlighted in the University of Oxford’s RECOVERY trial, yet it was notably absent from the World Health Organization’s SOLIDARITY trial. This review explores the pharmacological versatility of azithromycin, including its antibiotic, antimalarial, and antiviral properties, and discusses its history as among the most frequently repurposed drugs within the macrolide class. Additionally, we assess the clinical and socio-economic significance of azithromycin in the context of respiratory pandemics, presenting a model that clarifies its combinatorial way of action against COVID-19 pneumonia.
Keyword :
None